Hongmei Ji, Anqing Li#, Feng Wang


Department of Gastroenterology, People's Hospital of Linzi District, Zibo, PR China


Objective: More and more evidence suggests that HER2-neu is an important biomarker of gastric cancer (GC) and gastroesophageal (GEJ) adenocarcinoma. The purpose of this study was to evaluate the expression of HER2-neu and some clinicopathological features of gastric cancer and gastroesophageal carcinoma.

Methods: 211 paraffin-embedded tissues, 193 of which were GC and 18 were GEJ, were selected, and then 4mm sections were prepared for hematoxylin, eosin and IHC (Her2-neu) staining. Chi-square test was used to test the significant difference between the expression level of HER2-neu and clinicopathological parameters. 

Results: In patients with advanced cancer of GC and GEJ, the over-expression of HER2-neu was more correlated with the subtypes of colorectal cancer.

Conclusion: Biological marker Her2-neu may be used as a new supplementary therapy for GC and GEJ patients.


Biological marker, Her2-neu, gastric cancer (GC), gastroesophageal (GEJ) adenocarcinoma.